{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:33:53Z","timestamp":1770914033583,"version":"3.50.1"},"reference-count":85,"publisher":"Hindawi Limited","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":4024,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2004.00087.x","type":"journal-article","created":{"date-parts":[[2004,11,24]],"date-time":"2004-11-24T18:21:06Z","timestamp":1101320466000},"page":"1063-1072","source":"Crossref","is-referenced-by-count":20,"title":["Lipid-altering agents: the future"],"prefix":"10.1155","volume":"58","author":[{"given":"A.S.","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2004,8,25]]},"reference":[{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.ATV.19.2.187","article-title":"Systematic review on the risk and benefit of different cholesterol-lowering interventions","volume":"19","author":"Bucher","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0163-7258(03)00055-X","article-title":"The lipid and non-lipid effects of statins","volume":"99","author":"Wierzbicki","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/clinchem\/48.1.11","article-title":"Impact of the third cholesterol report from the adult treatment panel of the national cholesterol education program on the clinical laboratory","volume":"48","author":"Warnick","year":"2002","journal-title":"Clin Chem"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1185\/030079902125000165","article-title":"Beyond LDL-C - the importance of raising HDL-C","volume":"18","author":"Wierzbicki","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB6|cit6","doi-asserted-by":"crossref","unstructured":"Wierzbicki AS Mikhailidis DP Wray R et al. Statin-fibrate combination: therapy for hyperlipidaemia: a review Curr Med Res Opin 2003 19 155 6 10.1185\/030079903125001668","DOI":"10.1185\/030079903125001668"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB7|cit7","first-page":"153","article-title":"The post coronary artery bypass graft trial investigators","volume":"336","author":"The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","author":"MRC\/BHF.","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"28B","DOI":"10.1016\/S0002-9149(01)01454-0","article-title":"Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor","volume":"87","author":"McTaggart","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0002-9149(01)01727-1","article-title":"Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia","volume":"88","author":"Olsson","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1345\/aph.1A033","article-title":"Rosuvastatin for the treatment of patients with hypercholesterolemia","volume":"36","author":"Chong","year":"2002","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1742-1241.2001.tb11160.x","article-title":"Comparison of therapy with simvastatin 80\u2003mg and 120\u2003mg in patients with familial hypercholesterolaemia","volume":"55","author":"Wierzbicki","year":"2001","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1517\/13543784.9.11.2653","article-title":"NK-104: a novel synthetic HMG-CoA reductase inhibitor","volume":"9","author":"Kajinami","year":"2000","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/abbi.1994.1238","article-title":"Effect of squalene synthase inhibition on the expression of hepatic cholesterol biosynthetic enzymes, LDL receptor, and cholesterol 7 alpha hydroxylase","volume":"311","author":"Ness","year":"1994","journal-title":"Arch Biochem Biophys"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0014-2999(01)01450-9","article-title":"Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism","volume":"431","author":"Hiyoshi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB16|cit16","first-page":"193","article-title":"Editorial: Statins: myalgia and myositis","volume":"9","author":"Wierzbicki","year":"2002","journal-title":"Br J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/009127009803801205","article-title":"Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers","volume":"38","author":"Sharma","year":"1998","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1073\/pnas.90.1.80","article-title":"Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase","volume":"90","author":"Bergstrom","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB19|cit19","first-page":"746","article-title":"RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase","volume":"281","author":"Amin","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjp.0703545","article-title":"YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species","volume":"131","author":"Ugawa","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0167-5273(02)00561-2","article-title":"Imidazole derivatives as cholesterol-lowering agents","volume":"90","author":"Wierzbicki","year":"2003","journal-title":"Int J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-2952(01)00918-2","article-title":"Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor","volume":"63","author":"Taghibiglou","year":"2002","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/00041433-200106000-00008","article-title":"Roles of acyl-coenzyme A: cholesterol acyltransferase-1 and -2","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0022-2275(20)33494-5","article-title":"Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs","volume":"40","author":"Burnett","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1161\/01.CIR.103.13.1778","article-title":"Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice","volume":"103","author":"Delsing","year":"2001","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0021-9150(98)00046-X","article-title":"HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit","volume":"139","author":"Bocan","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0021-9150(00)00615-8","article-title":"Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia","volume":"157","author":"Insull","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0002-8703(02)00128-X","article-title":"Design features of the Avasimibe and Progression of coronary Lesions assessed by intravascular UltraSound (A-PLUS) clinical trial","volume":"144","author":"Tardif","year":"2002","journal-title":"Am Heart J"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB29|cit29","first-page":"1328","article-title":"Avasimibe Pfizer","volume":"3","author":"Burnett","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0022-2275(20)32526-8","article-title":"Evidence that microsomal triglyceride transfer protein is limiting in the production of apolipoprotein B-containing lipoproteins in hepatic cells","volume":"39","author":"Jamil","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1126\/science.282.5389.751","article-title":"An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits","volume":"282","author":"Wetterau","year":"1998","journal-title":"Science"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(01)01419-4","article-title":"MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion","volume":"431","author":"Shiomi","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/01.ATV.19.4.1051","article-title":"Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells","volume":"19","author":"Jin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0026-0495(99)90053-7","article-title":"Cholesterol reduction by different plant stanol mixtures and with variable fat intake","volume":"48","author":"Gylling","year":"1999","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"I. Reduction in incidence of coronary heart disease","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results.","year":"1984","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1742-1241.2002.tb11208.x","article-title":"Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management","volume":"56","author":"Leitersdorf","year":"2002","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0400441101","article-title":"Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport","volume":"101","author":"Smart","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1592\/phco.23.14.1463.31942","article-title":"Ezetimibe: a selective cholesterol absorption inhibitor","volume":"11","author":"Nutescu","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1056\/NEJM199010043231404","article-title":"Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)","volume":"323","author":"Buchwald","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0022-2275(20)30180-2","article-title":"BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis","volume":"43","author":"Edwards","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/01.ATV.18.8.1304","article-title":"Inhibition of ileal Na+\/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits","volume":"18","author":"Higaki","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9149(02)02436-0","article-title":"The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations","volume":"90","author":"Sacks","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1046\/j.1365-2362.2000.00734.x","article-title":"Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X","volume":"30","author":"Idzior-Walus","year":"2000","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1021\/jm010143b","article-title":"(-)3-[4-[2-(Phenoxazin-10-yl) ethoxy]phenyl]-2-ethoxypropanoic acid [(-) DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity","volume":"44","author":"Lohray","year":"2001","journal-title":"J Med Chem"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/sj.bjp.0703328","article-title":"Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats","volume":"130","author":"Shibata","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diabetes.51.4.1083","article-title":"A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha\/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models","volume":"51","author":"Etgen","year":"2002","journal-title":"Diabetes"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"E966","DOI":"10.1152\/ajpendo.00149.2002","article-title":"Combination therapy with PPARgamma and PPARalpha agonists increases glucose-stimulated insulin secretion in db\/db mice","volume":"284","author":"Yajima","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB50|cit50","first-page":"444","article-title":"MK-767. Kyorin\/Banyu\/Merck","volume":"4","author":"Calkin","year":"2003","journal-title":"Curr Opin Invest Drugs"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E, after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/01.CIR.0000014682.14181.F2","article-title":"Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI) -Prevenzione","volume":"105","author":"Marchioli","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041433-199908000-00006","article-title":"Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein","volume":"10","author":"Morton","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/35018119","article-title":"A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits","volume":"406","author":"Okamoto","year":"2000","journal-title":"Nature"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1161\/01.CIR.0000015857.31889.7B","article-title":"Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study","volume":"105","author":"De Grooth","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1056\/NEJMoa031766","article-title":"Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol","volume":"350","author":"Brousseau","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0021-9150(03)00137-0","article-title":"The safety and immunogenicity of a CETP vaccine in healthy adults","volume":"169","author":"Davidson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1023\/A:1007111830472","article-title":"High density lipoprotein, apolipoprotein A-I, and coronary artery disease","volume":"209","author":"Srivastava","year":"2000","journal-title":"Mol Cell Biochem"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1567-5688(02)00044-2","article-title":"HDL therapy for the acute treatment of atherosclerosis","volume":"3","author":"Newton","year":"2002","journal-title":"Atheroscler Suppl"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00041433-200304000-00007","article-title":"Apolipoprotein A-IMilano: current perspectives","volume":"14","author":"Chiesa","year":"2003","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0006-3495(00)76417-4","article-title":"Molecular belt models for the apolipoprotein A-I Paris and Milano mutations","volume":"79","author":"Klon","year":"2000","journal-title":"Biophys J"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissan","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1096\/fj.01-0273rev","article-title":"Oxidized LDL and HDL: antagonists in atherothrombosis","volume":"15","author":"Mertens","year":"2001","journal-title":"FASEB J"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJM200010193431603","article-title":"Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group","volume":"343","author":"Packard","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0960-894X(03)00058-1","article-title":"The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A (2)","volume":"13","author":"Blackie","year":"2003","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein (a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB67|cit67","first-page":"2633","article-title":"Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males","volume":"81","author":"Berglund","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1161\/01.ATV.0000055741.13940.15","article-title":"A synthetic peptide that inhibits lipoprotein (a) assembly","volume":"23","author":"Sharp","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1124\/jpet.102.048132","article-title":"AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent","volume":"305","author":"Sundell","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"41A","DOI":"10.1016\/S0002-9149(02)03149-1","article-title":"Clinical results with AGI-1067: a novel antioxidant vascular protectant","volume":"91","author":"Tardif","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1161\/01.CIR.0000047525.58618.3C","article-title":"Effects of AGI-1067 and probucol after percutaneous coronary interventions","volume":"107","author":"Tardif","year":"2003","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1136\/bmj.326.7404.1419","article-title":"A strategy to reduce cardiovascular disease by more than 80%","volume":"326","author":"Wald","year":"2003","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB73|cit73","unstructured":"Kastelein J What future for combination therapies? Int J Clin Pract Suppl 2003 45 50"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","author":"The Lipid Research Clinics Coronary Primary Prevention Trial results II.","year":"1984","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB75|cit75","first-page":"600","article-title":"WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up","volume":"2","year":"1984","journal-title":"Lancet"},{"issue":"Suppl. I","key":"10.1111\/j.1742-1241.2004.00087.x-BIB76|cit76","first-page":"1","article-title":"Helsinki heart study: a controlled coronary prevention trial. Design and baseline findings","volume":"8","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB78|cit78","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB80|cit80","first-page":"1349","article-title":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","volume":"339","author":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3949\/ccjm.64.7.347","article-title":"Lipid-lowering therapy after coronary artery bypass surgery: the Post-CABG trial","volume":"64","author":"Stewart","year":"1997","journal-title":"Cleve Clin J Med"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1185\/030079902125000787","article-title":"Treatment with atorvastatin to the National Cholesterol Educational Program goal versus \u2018usual\u2019 care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study","volume":"18","author":"Athyros","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2004.00087.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2004.00087.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2004.00087.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T20:18:37Z","timestamp":1705349917000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2004.00087.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,25]]},"references-count":85,"journal-issue":{"issue":"11"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2004.00087.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8,25]]}}}